An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies - Full Text View

Sponsor:	Celtic Pharma Development Services
Collaborator:	Neurobiological Technologies
Information provided by:	Celtic Pharma Development Services
ClinicalTrials.gov Identifier:	NCT00226655

Purpose

The purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone (Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to all patients who participate in either of the blinded studies, NTI 0302, NTI 0303, or other designated studies, including patients who may have discontinued blinded study medication early but completed the protocol-stipulated follow-up periods.

Condition	Intervention	Phase
Brain Edema Brain Tumor	Drug: hCRF [XERECEPT (corticorelin acetate injection)]	Phase III

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title:	An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies

Resource links provided by NLM:

MedlinePlus related topics: Brain Cancer Cancer Edema

Drug Information available for: Dexamethasone Dexamethasone acetate Doxiproct plus Corticorelin acetate Corticorelin ovine Dexamethasone Sodium Phosphate Corticotropin Corticotropin-releasing hormone

U.S. FDA Resources

Further study details as provided by Celtic Pharma Development Services:

Primary Outcome Measures:

The study will evaluate the overall long-term safety and tolerability of hCRF and steroid toxicities by monitoring dexamethasone dosing, laboratory values, adverse events,electrocardiograms and neurological and clinical status. [ Time Frame: Prospective ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	340
Study Start Date:	July 2005
Study Completion Date:	April 2009
Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
I: Experimental All patients will receive hCRF (XERECEPT) 2mg/day	Drug: hCRF [XERECEPT (corticorelin acetate injection)] 2mg/day

Detailed Description:

XERECEPT® is not a potential treatment for cancer, but may reduce the edema associated with tumors and as a result, decrease neurological symptoms.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Participation in and completion of stipulated final follow-up periods for study NTI 0302, NTI 0303, or other designated studies.
Have a Karnofsky Performance of > 50 at Baseline
Capable of self-administration of subcutaneous injections twice daily or availability of assistance from caregiver.
Ability to provide written informed consent or, if unable to provide, have a legal guardian or representative provide written informed consent.
For women of childbearing potential: a negative serum pregnancy test at Baseline

Exclusion Criteria:

Concurrent enrollment in any investigational drug or device study, other than NTI 0302, NTI 0303, or other designated studies.
Systemic steroid use for any indication other than peritumoral brain edema.
Use or intended use of dexamethasone as an anti-emetic during study.
Clinical signs and symptoms of cerebral herniation.
Serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrine metabolic disease which could put the patient at unusual risk during study participation.
Confounding previous or concurrent neurological disorders that would interfere with adequate clinical evaluation.
Clinically significant head injury or chronic seizure disorder, if the condition results in functional impairment or is likely to interfere with evaluations.(Maintenance anticonvulsant therapy is allowed)
Central nervous system (CNS) infection.
Pregnancy, breastfeeding and/or refusal to practice birth control while in study, for women of childbearing potential.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00226655

Show 32 Study Locations

Sponsors and Collaborators

Celtic Pharma Development Services

Neurobiological Technologies

Investigators

Principal Investigator:

William Shapiro, MD

Barrow Neurological Institute

More Information

No publications provided

Responsible Party:	Celtic Pharma Development Services ( Patrick O'Connor, MD - Medical Monitor )
Study ID Numbers:	NTI 0501
Study First Received:	September 23, 2005
Last Updated:	April 28, 2009
ClinicalTrials.gov Identifier:	NCT00226655 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Celtic Pharma Development Services:

peritumoral brain edema
edema
malignant brain tumor
astrocytoma

brain tumor
dexamethasone
Decadron

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Dexamethasone
Antineoplastic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Edema
Antiemetics
Central Nervous System Neoplasms
Brain Edema
Brain Diseases
Hormones
Signs and Symptoms
Neoplasms by Site
Therapeutic Uses

Nervous System Neoplasms
Corticotropin-Releasing Hormone
Antineoplastic Agents, Hormonal
Nervous System Diseases
Gastrointestinal Agents
Central Nervous System Diseases
Glucocorticoids
Pharmacologic Actions
Brain Neoplasms
Neoplasms
Autonomic Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 08, 2010